Refractory/Relapsing B-Cell Malignancies research hub

A study to investigate safety of INT2104 infusions in participants aged 18 years of age and older who have B-cell cancers that came back after previous treatment [INVISE]

This study is looking at a new treatment called INT2104 for adults with B-cell cancers that have returned or not responded to previous treatments. It's an early-stage study to check how safe this new treatment is for people.